Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Total Current Liabilities (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Total Current Liabilities for 16 consecutive years, with $12.3 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 20.82% to $12.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.3 million through Dec 2025, down 20.82% year-over-year, with the annual reading at $12.3 million for FY2025, 20.82% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $12.3 million at Plus Therapeutics, down from $13.6 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $18.8 million in Q2 2024, with the low at $4.9 million in Q1 2022.
  • Average Total Current Liabilities over 5 years is $10.7 million, with a median of $10.6 million recorded in 2025.
  • The sharpest move saw Total Current Liabilities surged 160.03% in 2023, then tumbled 61.06% in 2025.
  • Over 5 years, Total Current Liabilities stood at $9.5 million in 2021, then rose by 24.92% to $11.9 million in 2022, then fell by 9.49% to $10.7 million in 2023, then surged by 44.97% to $15.6 million in 2024, then fell by 20.82% to $12.3 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $12.3 million, $13.6 million, and $7.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.